Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 5, Pages 1132
Publisher
MDPI AG
Online
2021-03-08
DOI
10.3390/cancers13051132
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibitors of lipogenic enzymes as a potential therapy against cancer
- (2020) Nicolás Montesdeoca et al. FASEB JOURNAL
- Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer
- (2020) Javier A. Menendez et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Splicing factor ESRP1 controls ER‐positive breast cancer by altering metabolic pathways
- (2019) Yesim Gökmen‐Polar et al. EMBO REPORTS
- TCPA v3.0: An Integrative Platform to Explore the Pan-cancer Analysis of Functional Proteomic Data
- (2019) Mei-Ju May Chen et al. MOLECULAR & CELLULAR PROTEOMICS
- Pathways to Endocrine Therapy Resistance in Breast Cancer
- (2019) Md. Moquitul Haque et al. Frontiers in Endocrinology
- Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors
- (2018) Jamie N Mills et al. CURRENT OPINION IN PHARMACOLOGY
- The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model
- (2018) Efthymia Papaevangelou et al. INTERNATIONAL JOURNAL OF CANCER
- Fatty acid synthase (FASN) as a therapeutic target in breast cancer
- (2017) Javier A. Menendez et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Fatty acid synthase – Modern tumor cell biology insights into a classical oncology target
- (2017) Douglas Buckley et al. PHARMACOLOGY & THERAPEUTICS
- Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer
- (2017) Kazuhiro Araki et al. Breast Cancer
- Fatty acid synthase regulates estrogen receptor-α signaling in breast cancer cells
- (2017) J A Menendez et al. Oncogenesis
- FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression
- (2017) Timothy S. Heuer et al. EBioMedicine
- Molecular Pathways: Fatty Acid Synthase
- (2015) S. F. Jones et al. CLINICAL CANCER RESEARCH
- Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies
- (2015) Weimin Fan et al. Future Medicinal Chemistry
- Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer
- (2015) Dirk O Bauerschlag et al. Journal of Translational Medicine
- Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs
- (2015) Adriana Blancafort et al. PLoS One
- Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression
- (2015) Richard Ventura et al. EBioMedicine
- Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer
- (2014) Eva Maria Ciruelos Gil CANCER TREATMENT REVIEWS
- Fatty acid synthase causes drug resistance by inhibiting TNF-α and ceramide production
- (2013) Hailan Liu et al. JOURNAL OF LIPID RESEARCH
- TCPA: a resource for cancer functional proteomics data
- (2013) Jun Li et al. NATURE METHODS
- Fatty acid synthase as a potential therapeutic target in cancer
- (2010) Richard Flavin et al. Future Oncology
- Molecular Mechanism and Clinical Implications of Endocrine Therapy Resistance in Breast Cancer
- (2010) Grazia Arpino et al. ONCOLOGY
- Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer
- (2009) Sherene Loi et al. BMC Medical Genomics
- Fatty Acid Synthase: Association with Insulin Resistance, Type 2 Diabetes, and Cancer
- (2009) J. A. Menendez et al. CLINICAL CHEMISTRY
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
- (2009) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells
- (2008) Bin Chen et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells
- (2008) Richard J. Santen et al. STEROIDS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search